Efficacy and Safety of Direct-Acting Antivirals in Elderly Patients with Chronic Hepatitis C: A Nationwide Real-Life, Observational, Multicenter Study from Turkey
Yükleniyor...
Dosyalar
Tarih
2022
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
AVES
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Background: The number and proportion of elderly patients living with chronic hepatitis C are expected to increase in the coming years. We aimed to compare the real-world efficacy and safety of direct-acting antiviral treatment in elderly and younger Turkish adults infected with chronic hepatitis C. Methods: In this multicenter prospective study, 2629 eligible chronic hepatitis C patients treated with direct-acting antivirals between April 2017 and December 2019 from 37 Turkish referral centers were divided into 2 age groups: elderly (?65 years) and younger adults (<65 years) and their safety was compared between 2 groups in evaluable population. Then, by matching the 2 age groups for demographics and pretreatment risk factors for a non-sustained virological response, a total of 1516 patients (758 in each group) and 1244 patients (622 in each group) from the modified evaluable population and per-protocol population were included in the efficacy analysis and the efficacy was compared between age groups. Results: The sustained virological response in the chronic hepatitis C patients was not affected by the age and the presence of cirrhosis both in the modified evaluable population and per-protocol population (P = .879, P = .508 for modified evaluable population and P = .058, P = .788 for per-protocol population, respectively). The results of the per-protocol analysis revealed that male gender, patients who had a prior history of hepatocellular carcinoma, patients infected with non-genotype 1 hepatitis C virus, and patients treated with sofosbuvir+ribavirin had a significantly lower sustained virological response 12 rates (P < .001, P = .047, P = .013, and P = .025, respectively). Conclusion: Direct-acting antivirals can be safely used to treat Turkish elderly chronic hepatitis C patients with similar favorable efficacy and safety as that in younger adults. Copyright @ Author(s)
Açıklama
Anahtar Kelimeler
Age, chronic hepatitis C, direct-acting antiviral agents, elderly, Turkey, antivirus agent, dasabuvir plus ombitasvir plus paritaprevir plus ritonavir, ledipasvir plus sofosbuvir, ribavirin, sofosbuvir, antivirus agent, ribavirin, sofosbuvir, adult, aged, anemia, angioneurotic edema, Article, bleeding, chronic hepatitis C, cohort analysis, constipation, decompensated liver cirrhosis, demography, drug efficacy, drug safety, drug withdrawal, dyspnea, fatigue, female, groups by age, headache, Hepatitis C virus genotype 1, human, hyperbilirubinemia, insomnia, liver cell carcinoma, liver cirrhosis, major clinical study, male, medical history, middle aged, multicenter study, nausea, nonhuman, observational study, population research, prospective study, pruritus, psychosis, sex difference, sustained virologic response, Turkey (republic), urticaria, young adult, chronic hepatitis C, clinical trial, combination drug therapy, genetics, Hepacivirus, treatment outcome, turkey (bird), Adult, Aged, Antiviral Agents, Drug Therapy, Combination, Hepacivirus, Hepatitis C, Chronic, Humans, Male, Prospective Studies, Ribavirin, Sofosbuvir, Sustained Virologic Response, Treatment Outcome, Turkey
Kaynak
Turkish Journal of Gastroenterology
WoS Q Değeri
Q4
Scopus Q Değeri
Q3
Cilt
33
Sayı
10
